Controlling sugars and insulin to reduce cancer risk: what we know today

Editor's note: This article was originally published in the past and has been updated to integrate and clarify available scientific evidence. The content is for informational and educational purposes only and does not replace the advice of your doctor. For clinical clarifications, it is always recommended to consult with healthcare professionals.

IN BRIEF

• Excess weight and increased body mass index (BMI) are associated with a higher risk for several types of cancer; the relationship is complex and depends on anatomical site, sex, and context.
• Proposed mechanisms include hyperinsulinemia, IGF signaling, low-grade inflammation, and alterations in cytokines and adipokines.
• Mendelian randomization genetic studies suggest that higher fasting insulin levels may contribute, in some cancers (e.g., endometrium, colon), to an increased risk.
• Physical activity and weight control are interventions that reduce metabolic factors associated with risk; their recommendation remains general and not a specific therapeutic for cancer.

Abstract: what does science say?

The relationship between sugars, insulin, and cancer risk is the subject of intense study. In simple terms: obesity and increased systemic insulin secretion (hyperinsulinemia) are observationally associated with an increased risk for several cancers; plausible biological mechanisms include activation of the insulin/IGF pathway, modulation of sex hormones, and chronic inflammation derived from adipose tissue. Genetic studies that reduce observational biases (Mendelian randomization) provide supporting evidence for the causal capacity of insulin for some cancers, but the strength and generalizability of the conclusions vary by tumor site. The main limitations are the observational nature of much research, the heterogeneity of studies, and the complexity of individual metabolic factors.

Why sugars and insulin are considered relevant factors for cancer

Epidemiological literature shows a repeated association between increased adiposity (measured by BMI or visceral fat indicators) and the incidence of numerous cancers, with variations by site and population. A systematic meta-analysis of prospective studies quantified risk increases in relation to BMI for various cancers, highlighting the robustness of the observational association at the population level [1]. Data from vast cohorts confirm the impact of excess weight on both general cancer mortality and individual anatomical sites [2]. The biological hypotheses linking sugars/insulin and cancer are based on two main lines: (1) hyperinsulinemia and overactivation of the insulin/IGF pathway can promote cell proliferation and reduce apoptosis; and (2) excess adipose tissue produces cytokines and adipokines that promote an inflammatory environment conducive to tumorigenesis [3][4]. These mechanisms do not automatically imply that sugar consumption itself is a direct cause of cancer: the pathway is mediated by body weight, metabolism, and duration of exposure.

Epidemiological evidence

Prospective studies and meta-analyses have documented significant relationships between increased BMI and the risk of various cancers (e.g., endometrium, esophageal adenocarcinoma, colon, kidneys), with increasing risk ratios for every 5 kg/m2 increase [1]. Large population cohorts have also shown that excess weight contributes to an increase in cancer mortality in both sexes [2]. Such observations are consistent but remain susceptible to residual confounding and imperfect measurements of metabolic exposure.

Plausible biological mechanisms: insulin, IGF, and metabolic pathways

Insulin and related growth factors (IGF) activate intracellular pathways (PI3K–AKT–mTOR and MAPK) known to promote cell growth and survival. Reviews and syntheses of mechanisms show how nutritional excess and hyperinsulinemia can fuel these pathways, contributing to neoplastic progression in predisposed tissues [4]. Furthermore, altered adipose microenvironment modifies hormonal and metabolic signals that can favor tumor initiation and progression [3].

Inflammation, adipose tissue, and immune factors

Excess adipose tissue is not just an energy depot: it is an endocrine organ that secretes adipokines, chemokines, and pro-inflammatory molecules. It is a consolidated concept that chronic low-grade inflammation associated with obesity can contribute to carcinogenesis, modulating proliferation, angiogenesis, and extracellular matrix remodeling [5]. The production of pro-inflammatory cytokines and the presence of activated immune cells in adipose tissue create a microenvironment favorable to cellular transformation and tumor progression. This dynamic plausibly links metabolism, immunity, and oncological risk biologically, while still requiring interpretive caution in direct transfer from the biological model to the clinical effect.

BAFF and immunometabolic signals

B cell-activating factor (BAFF) is a TNF family cytokine that has been identified as produced by adipose tissue and associated with metabolic dysfunction. Experimental and observational studies indicate that BAFF can alter adipokine production and contribute to insulin resistance; in murine models, BAFF manipulation modifies insulin sensitivity and adipose inflammation [6]. These data suggest a possible role as an immunometabolic mediator between obesity and metabolic disorders relevant to oncological risk, but clinical translation requires further confirmation.

What evidence supports a causal role for insulin?

To assess causality beyond association, several genetic studies (Mendelian randomization) have tested whether genetic predispositions to higher insulin levels or other glycometabolic traits are associated with cancer risk. MR analyses on the endometrium have suggested a causal effect of higher fasting insulin levels on increased risk of endometrial carcinoma [8]. Similar analyses for colorectal carcinoma provide results supporting a role for glycemia/insulin in some subtypes, but not for all tumors examined [9]. These genetic evidences reduce some sources of bias typical of observational studies, but remain subject to limitations inherent in the MR design (pleiotropy of genetic instruments, statistical power). In summary, the totality of the data suggests that hyperinsulinemia is a plausible and partially causal mediator for some cancers, especially where hormone-metabolic mechanisms are recognized (e.g., endometrium) [8][9].

Epidemiological interpretation: dose, frequency, and context

The role of insulin depends on the intensity and duration of metabolic exposure, the distribution of body fat (visceral vs. subcutaneous), and individual factors such as age, sex, and hormonal history. The risk is not uniform: for example, increased BMI affects the risk of endometrium, esophagus, and colon differently. For this reason, each indication must be placed in the clinical and demographic context of the individual subject [1][2][9].

What it means in practice

The evidence does not support simplistic considerations or the promise that merely reducing dietary sugars will eliminate cancer risk. However, adopting measures that reduce insulin resistance and adiposity — along with other health benefits — is consistent with evidence-based prevention principles. Regular physical activity and maintaining an appropriate body weight are associated with reductions in the risk of multiple types of cancer in large observational studies [7]. Targeted interventions (for example, significant weight loss, medical therapy in subjects with diabetes) can modify metabolic biomarkers known to be associated with tumor risk; mediation studies suggest that part of the effect of BMI on the risk of some cancers is mediated by factors such as fasting insulin [10]. Important: these observations do not constitute personalized therapeutic indications. Choices about weight, diet, or drug interventions must be made with a doctor, evaluating benefits and risks in each individual case.

KEY POINTS TO REMEMBER

• Obesity is robustly and documentedly associated with an increased risk of various cancers; the link is heterogeneous by site and population [1][2].
• Hyperinsulinemia and IGF signaling are plausible biological mechanisms that can promote proliferative processes and reduce apoptosis [3][4].
• Chronic inflammation linked to adipose tissue and immunometabolic factors (e.g., BAFF) contribute to the biological picture linking metabolism and cancer [5][6].
• Genetic studies (Mendelian randomization) provide partial support for a causal role of insulin in some cancers, with methodological limitations to consider [8][9].
• Physical activity and weight control are measures with overall health benefits and evidence of risk reduction for various cancers; they remain general recommendations, not specific oncological prescriptions [7].

Limitations of the evidence

It is essential to distinguish between types of evidence. Observational studies show associations but can be influenced by confounding (lifestyles, access to care, socioeconomic factors) and imprecise measurements of exposure and adiposity. Systematic reviews and meta-analyses increase the precision of estimates but inherit the limitations of individual studies [1][2]. Mendelian randomization analyses offer advantages in reducing bias from unmeasured confounding, but depend on the validity and specificity of the genetic instruments used; pleiotropy can compromise causal interpretation [8][9]. The proposed biological mechanisms (insulin/IGF, inflammation, adipokines) are plausible and supported by experimental and preclinical data, but their relative importance varies by tumor type and subject [3][4][5]. In conclusion, interpretive caution is necessary: many questions remain open and require well-designed studies, randomized interventions, and integrated approaches.

Editorial conclusion

Converging research indicates that metabolism, insulin, and adipose tissue are key elements in the relationship between obesity and the risk of some cancers. The practical message for the general public is cautious and oriented towards global health: adopting a lifestyle that reduces excess adiposity and improves insulin sensitivity is consistent with the prevention of chronic diseases, including many forms of cancer. However, individual choices should always be discussed with healthcare professionals and integrated into an overall assessment of personal risk factors.

Editor's note: editorial and scientific update for informational purposes. This text does not replace personalized medical advice or therapies.

SCIENTIFIC RESEARCH

1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578. https://doi.org/10.1016/S0140-6736(08)60269-X
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638. https://doi.org/10.1056/NEJMoa021423
3. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11(12):886–895. https://doi.org/10.1038/nrc3174
4. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159–169. https://doi.org/10.1038/nrc3215
5. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. https://doi.org/10.1038/nature01322
6. Winer DA, et al. B cell-activating factor controls the production of adipokines and induces insulin resistance. Obesity (Silver Spring). 2012;20(1):176–185. https://doi.org/10.1038/oby.2011.165
7. Moore SC, Lee IM, Weiderpass E, et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med. 2016;176(6):816–825. https://doi.org/10.1001/jamainternmed.2016.1548
8. Nead KT, et al. Evidence of a causal association between insulinemia and endometrial cancer: a Mendelian randomization analysis. J Natl Cancer Inst. 2015;107(9):djv178. https://doi.org/10.1093/jnci/djv178
9. Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis. J Natl Cancer Inst. 2022;114(5):740–751. https://doi.org/10.1093/jnci/djac011
10. Hu Y, et al. Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis. BMC Med. 2022;20(1):223. https://doi.org/10.1186/s12916-022-02322-3